# Acadia Pharmaceuticals Inc. (ACAD)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $3.61B  
**Price:** $21.25 (-2.70%)

> Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing medicines for neurological disorders and rare diseases. The company’s primary purpose is to address conditions with significant unmet medical needs, particularly in central nervous system indications. Acadia’s commercial portfolio includes FDA-approved therapies for Parkinson’s disease psychosis and Rett syndrome, targeting patients who often have limited treatment options. Beyond its marketed products, Acadia is actively engaged in clinical development programs in areas such as Alzheimer’s disease psychosis and Lewy body dementia psychosis, as well as additional early-stage programs in other underserved neurological conditions. Headquartered in San Diego, California, Acadia serves healthcare providers, patients, and caregivers through a combination of proprietary research, regulatory expertise, and specialized commercial capabilities. The company plays a notable role in the biopharmaceutical market segment focused on neuroscience and orphan diseases, contributing differentiated therapies to a highly specialized treatment landscape.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $1.07B | — | $105M | $391M | — |
| 2024 | $958M | — | $231M | $226M | — |
| 2023 | $726M | $685M | -$73M | -$61M | — |
| 2022 | $517M | $507M | -$224M | -$216M | — |
| 2021 | $484M | $473M | -$170M | -$168M | — |
| 2020 | $442M | $432M | -$287M | -$282M | — |
| 2019 | $339M | $328M | -$247M | -$235M | — |
| 2018 | $224M | $211M | -$247M | -$245M | — |
| 2017 | $125M | $116M | -$292M | -$289M | — |
| 2016 | $17M | $14M | -$273M | -$271M | — |
| 2015 | $61,000 | — | -$165M | -$164M | — |
| 2014 | $120,000 | — | -$93M | -$92M | — |
| 2013 | $1M | — | -$38M | -$38M | — |
| 2012 | $5M | — | -$21M | -$21M | — |
| 2011 | $2M | — | -$23M | -$23M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $1.56B | $337M | $1.23B | $178M | — |
| 2024 | $1.19B | $455M | $733M | $320M | — |
| 2023 | $749M | $317M | $432M | $189M | — |
| 2022 | $588M | $187M | $400M | $115M | — |
| 2021 | $700M | $159M | $541M | $147M | — |
| 2020 | $783M | $156M | $627M | $326M | — |
| 2019 | $783M | $84M | $699M | $190M | — |
| 2018 | $540M | $61M | $479M | $135M | — |
| 2017 | $385M | $49M | $335M | $69M | — |
| 2016 | $561M | $43M | $518M | $164M | — |
| 2015 | $222M | $22M | $200M | $102M | — |
| 2014 | $325M | $16M | $309M | $62M | — |
| 2013 | $189M | $7M | $182M | $12M | — |
| 2012 | $109M | $6M | $85M | $58M | — |
| 2011 | $32M | $9M | $23M | $7M | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | $110M | $5M | $105M |
| 2024 | $158M | $523,000 | $157M |
| 2023 | $17M | $50,000 | $17M |
| 2022 | -$114M | — | -$114M |
| 2021 | -$126M | $1M | -$127M |
| 2020 | -$136M | $8M | -$144M |
| 2019 | -$151M | $1M | -$152M |
| 2018 | -$167M | $2M | -$170M |
| 2017 | -$218M | $812,000 | -$219M |
| 2016 | -$208M | $2M | -$210M |
| 2012 | -$22M | — | — |
| 2011 | -$20M | $3,000 | -$20M |
| 2010 | -$11M | — | — |
| 2009 | -$14M | — | — |

Source: [CompaniesByCap](https://companiesbycap.com/company/ACAD)